Raghib Hussain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Raghib Hussain has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Kashif Abbas
Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University, Aligarh 202001, India
1 shared publication - Mohd Mustafa
Department of Biochemistry JN Medical College Aligarh Muslim University Aligarh India
1 shared publication - Mudassir Alam
Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University, Aligarh, India
1 shared publication - Nazura Usmani
Aligarh Muslim University
1 shared publication - Safia Habib
Aligarh Muslim University
1 shared publication - Tanwir Akhtar
Department of Public Health, College of Health Sciences, Saudi Electronic University
1 shared publication
Latest Publications
- 10 October 2025
- Published by Bentham Science Publishers Ltd. in Current Psychiatry Research and Reviews
- Vol. 22, 1-25
Management of Major Depressive Disorder by Citalopram: A Double-edged Sword
Major depressive disorder (MDD) affects over 280 million people globally, presenting a significant public health challenge. This review evaluates the use of citalopram, a selective serotonin reuptake inhibitor (SSRI), in MDD management, focusing on its therapeutic efficacy and the critical adverse effect of citalopram-induced hyponatremia (CIH). Through a comprehensive literature analysis, we explore the medicinal chemistry of citalopram, its mode of action, and the mechanisms underlying CIH, primarily associated with the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Findings indicate that CIH affects 9-40% of patients, with a higher prevalence in vulnerable populations such as the elderly and cancer patients, where it complicates treatment due to interactions with disease-related factors. Routine serum sodium monitoring is recommended for individuals at risk to mitigate potential risks. The review highlights the need for tailored treatment strategies to balance citalopram’s benefits against CIH risks, particularly in cancer patients, and identifies future research directions for personalized MDD management.
- 10 October 2025
- Published by Bentham Science Publishers Ltd. in Current Psychiatry Research and Reviews
- Vol. 22, 1-25
Management of Major Depressive Disorder by Citalopram: A Double-edged Sword
Major depressive disorder (MDD) affects over 280 million people globally, presenting a significant public health challenge. This review evaluates the use of citalopram, a selective serotonin reuptake inhibitor (SSRI), in MDD management, focusing on its therapeutic efficacy and the critical adverse effect of citalopram-induced hyponatremia (CIH). Through a comprehensive literature analysis, we explore the medicinal chemistry of citalopram, its mode of action, and the mechanisms underlying CIH, primarily associated with the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Findings indicate that CIH affects 9-40% of patients, with a higher prevalence in vulnerable populations such as the elderly and cancer patients, where it complicates treatment due to interactions with disease-related factors. Routine serum sodium monitoring is recommended for individuals at risk to mitigate potential risks. The review highlights the need for tailored treatment strategies to balance citalopram’s benefits against CIH risks, particularly in cancer patients, and identifies future research directions for personalized MDD management.